Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Receives Additional Delisting Notice from Nasdaq, Initiates Stock Split

SAN FRANCISCO, Jan. 15 - Lynx Therapeutics said today that has received notice from Nasdaq that it is in additional danger of delisting.

 

Nasdaq determined that Lynx was not in compliance with Nasdaq's audit committee requirements for continued listing. This notice comes on the heels of Lynx stock falling below Nasdaq's minimum bid price for continued listing.

 

Lynx has been granted a hearing before a Nasdaq panel to review the audit committee's decision.

 

Lynx said it was appointing an independent director to its audit committee at its next regularly scheduled board of directors meeting and that it expects to be in compliance with Nasdaq's audit committee requirements as defined by Nasdaq's Marketplace Rule 4350(d)(2).

 

Lynx also announced today that it will be initiating a reverse split of its stock. A 1-for-7 reverse split of its common stock was approved by its board of directors and stockholders and will take effect January 16. The split will reduce the number of common stock outstanding from about 32.5 million to 4.6 million, according to Lynx. Lynx will temporarily trade under the symbol LYNXD until reverting back to LYNX around February 13, the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more